Synthesis and biological activity of pyrazolo[3,4-d]thiazolo[3,2-a]pyrimidin-4-one derivatives: in silico approach

References

• Ling L. Xanthine oxidase. Free Radic Biol Med 2001;77(222):1–10.
   Google Scholar
• Khobragade CN, Bodade RG, Shinde MS, Jaju DR, Bhosle RB, Dawane BS. Microbial and xanthine dehydrogenase inhibitory activity of some flavones. J Enzyme Inhib Med Chem 2008;23:341–6.
   PubMed Web of Science ®Google Scholar
• Rundles RW, Wyngaarden JB, Hitchings GH, Elion GB. Drugs and uric acid. Annu Rev Pharmacol 1969;9:345–62.
   PubMedGoogle Scholar
• Tamta H, Kalra S, Mukhopadhyay AK. Biochemical characterization of some pyrazolpyrimidine-based inhibitors of xanthine oxidase. Biochem 2006;71:S49–54.
   PubMed Web of Science ®Google Scholar
• Choil HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med 2005;143:499–516.
   PubMed Web of Science ®Google Scholar
• Choi HK, Curhan G. Gout: epidemiology and lifestyle choices. Curr Opin Rheumatol 2005;17:341–5.
   PubMed Web of Science ®Google Scholar
• Wortmann RL. Gout and hyperuricemia. Curr Opin Rheumatol 2002;14:281–6.
   PubMed Web of Science ®Google Scholar
• Terkeltaub RA. Gout in 2006. Bull NYU Hosp Jt Dis 2006;64:82–6.
   PubMedGoogle Scholar
• Saag KG, Mikuls TR. Recent advances in the epidemiology of gout. Curr Rheumatol Rep 2005;7:235–41.
   PubMedGoogle Scholar
• Lawrence RC, Helmick CG, Arnett FC. Estimation of the prevalence of arthritis and selected musculoskeletal disorders in the US. Arth Rheumtol 1998;41:778–99.
   PubMed Web of Science ®Google Scholar
• Mikuls TR, Farrar JT, Bilker WB, et.al. The treatment of asymptomatic hyperuricemia: results from the population based General Practice Research Database (GPRD). Arth Rheumtol 2003;48(Suppl. 9):S612.
   PubMed Web of Science ®Google Scholar
• Johnson RJ, Rideout BA. Uric acid and diet-insights into the epidemic of cardiovascular disease. N Engl J Med 2004;350:1071–3.
   PubMed Web of Science ®Google Scholar
• Underwood M. Clinical review: diagnosis and management of gout. BMJ 2006;332:1315–19.
   PubMed Web of Science ®Google Scholar
• Bomalaski JS, Clark MA. Serum uric acid-lowering therapies: where are we heading in management of hyperurecemia and the potential role of uricase. Curr Rheumatol Rep 2004;6:240–7.
   PubMedGoogle Scholar
• Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmocol Rev 2006;58:87–114.
   PubMed Web of Science ®Google Scholar
• Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF. An extremely potent inhibitor of XOR, crystal structure of the enzyme inhibitor complex and mechanism of inhibition. J Biol Chem 2003;278:1848–55.
   PubMed Web of Science ®Google Scholar
• Kuang-Hui Yu. Febuxostate: a novel non-purine selective inhibitor of xanthine oxides for the treatment of hyperuricemia in gout. Recent Pat Inflamm Allergy Drug Discov 2007;1:69–75.
   PubMedGoogle Scholar
• Nuki G, Simkin PA. A concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther 2006;8:11–15.
   Web of Science ®Google Scholar
• Borges F, Fernandes E, Roleira R. Progress towards the discovery of xanthine oxidase inhibitors. Curr Med Chem 2002;9:195–217.
   PubMed Web of Science ®Google Scholar
• Terkeltaub RA. Clinical practice. Gout. N Engl J Med 2003;349:1647–55.
   PubMed Web of Science ®Google Scholar
• El-Assiery SA, Sayed GH, Fouda A. Synthesis of some new annulated pyrazolo-pyrido (or pyrano) pyrimidine, pyrazolopyridine and pyranopyrazole derivatives. Acta Pharm 2004;54:143–50.
   PubMedGoogle Scholar
• Marel MG. Some reactions of pyrazolo(1,5-C)pyrimidinethiones. J Isla Acad Sci 1993;6(1):8–14.
   Google Scholar
• Oliveira-Campos AMF, Salaheldin AM, Rodrigues LM. Synthesi of some novel pyrazolo(3,4-d)pyrimidine derivatives. ARKIVOC 2007;16:92–100.
   Web of Science ®Google Scholar
• Feigelson P, Davidson JD, Robins RK. Pyrazolopyrimidines as inhibitors and substrates of xanthine oxidase. J Biol Chem 1956;12:993–1000.
   Google Scholar
• Rathish IG, Javed K, Ahmad S, Bano S, Alam MS, Pillai KK, et al. Synthesis and anti-inflammatory activity of some new 1,3,5-trisubstituted pyrazolines bearing benzene sulfonamide. Bioorg Med Chem Lett 2009;19:255–8.
   PubMed Web of Science ®Google Scholar
• Sidique S, Ardecky R, Ying Su, Narisawa S, Brown B, Millan JL, et al. Design and synthesis of pyrazole derivatives as potent and selective inhibitors of tissue-nonspecific alkaline phosphatase (TNAP). Bioorg Med Chem Lett 2009;19:222–225.
   PubMed Web of Science ®Google Scholar
• Shishoo CJ, Ravikumar T, Jain KS, Rathod IS, Gandhi TP, Satia MC. Synthesis of novel 1,2-(un)substituted-3-amino-5-aryl-6-arylaminopyrazolo[3,4-d]pyrimidine-4-(5H)-ones and their biological activity. Indian J Chem 1999;38(B):1075–85.
   Google Scholar
• Kalwadia B, Ora S, Kishore W. Synthesis of condensed pyrido[1,2-a]pyrimidine and pyrimido[4,5-d]pyrimidine derivatives from cyanoketene dithioacetal. Int J Chem Sci 2008;1:166–78.
   Google Scholar
• Chen XB, Gomes MJ. Estimation of Microbial Protein Supply to Sheep and Cattle Based on Urinary Excretion of Purine Derivatives: An Overview of the Technical Details. Aberdeen, Scotland: International Feed Resources Unit, 1992:1–21.
   Google Scholar
• Bergmeyer HU, Gawehn K, Grassl M. Enzymatic assay of Xanthine oxidase, In: Methods of Enzymatic Analysis, New York: Academic Press, 1974; 2 ed. I:521–2.
   Google Scholar
• Tomohisa N, Hiroo Y, Takayuki F, Kazuki E, Haruhiko M. Novel xanthine oxidase inhibitor studies: Part 2. Synthesis and xanthine oxidase inhibitory activities of 2-substituted 6-alkyl-idenehydrazino- or 6- arylmethyllidenehydrazino-7H-purines and 3- and/or 5-substituted 9H-1,2,4-triazolo[3,4-i]purines. J Chem Soc Perkin Trans 1999;1:3117–25.
   Google Scholar
• BioMed Cache 6.1, Molecular Modeling Programme Package. Tokyo: Fujitsu Ltd, 2006.
   Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46: 3–26.
   PubMed Web of Science ®Google Scholar
• Leal B, Afonso IF, Rodrigues CR, Abreu PA, Garrett R, Pinheiro LC, et al. Antibacterial profile against drug-resistance Staphylococcus epidermidis clinical strain and structure-activity relationship studies of 1H-pyrazolo[3,4-b]pyridine and thieno[2,3-b]pyridine derivatives. Bioorg Med Chem 2008;16:8196–204.
   PubMed Web of Science ®Google Scholar
• Sato T, Ashizawa N, Iwanaga T, Nakamura H, Matsumoto K, Inoue T, et al. Design, synthesis and pharmacological and pharmacokinetic evaluation of 3-phenyl-5-pyridyl-1,2,4-triazol derivatives as xanthine oxidoreductase inhibitors. Bioorg Med Chem Lett 2009;19:184–7.
   PubMed Web of Science ®Google Scholar